Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KLDONASDAQ:LIANNASDAQ:ORTXNASDAQ:PHXM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKLDOKaleido Biosciences$0.00$0.00$0.00▼$0.25$4K-0.065,042 shs250 shsLIANLianBio$0.20-2.1%$0.22$0.27▼$4.99$21.15M0.231.04 million shs14,001 shsORTXOrchard Therapeutics$16.70$16.59$4.24▼$16.72$380.09M0.55157,287 shsN/APHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKLDOKaleido Biosciences0.00%0.00%0.00%0.00%0.00%LIANLianBio0.00%+3.41%+3.52%-26.61%-95.96%ORTXOrchard Therapeutics0.00%0.00%0.00%0.00%0.00%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AN/AN/AN/AORTXOrchard TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKLDOKaleido Biosciences 0.00N/AN/AN/ALIANLianBio 0.00N/AN/AN/AORTXOrchard Therapeutics 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKLDOKaleido Biosciences$1.10M0.00N/AN/AN/A∞LIANLianBioN/AN/AN/AN/A$2.71 per shareN/AORTXOrchard Therapeutics$22.66M16.77N/AN/A$7.74 per share2.16PHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/ALIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AORTXOrchard Therapeutics-$150.66M-$0.94N/AN/AN/A-333.90%-74.94%-33.51%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKLDOKaleido BiosciencesN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AORTXOrchard TherapeuticsN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKLDOKaleido BiosciencesN/AN/AN/ALIANLianBioN/A10.0610.06ORTXOrchard Therapeutics0.203.122.98PHXMPHAXIAM Therapeutics0.231.78N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKLDOKaleido Biosciences81.56%LIANLianBio74.85%ORTXOrchard Therapeutics29.90%PHXMPHAXIAM Therapeutics0.40%Insider OwnershipCompanyInsider OwnershipKLDOKaleido Biosciences9.00%LIANLianBio7.59%ORTXOrchard Therapeutics2.91%PHXMPHAXIAM Therapeutics1.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKLDOKaleido Biosciences8042.62 million38.79 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionableORTXOrchard Therapeutics16622.76 million22.10 millionOptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataORTX, LIAN, PHXM, and KLDO HeadlinesRecent News About These CompaniesPHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results PublicationMarch 6, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Press Release Regarding Suspension of TradingMarch 6, 2025 | finance.yahoo.comPHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage TherapyJanuary 31, 2025 | businesswire.comPHAXIAM Therapeutics Announces Its Financial Calendar for 2025January 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in EuropeJanuary 7, 2025 | finance.yahoo.comPHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical StudyDecember 31, 2024 | finance.yahoo.comPHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy areaNovember 27, 2024 | globenewswire.comPHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"November 18, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | finanznachrichten.dePHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | globenewswire.comPHAXIAM Therapeutics S.A. (PHXM.PA)November 6, 2024 | finance.yahoo.comPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.November 4, 2024 | globenewswire.comPHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 studyOctober 9, 2024 | finance.yahoo.comPhaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update For the First Half of 2024September 26, 2024 | finanznachrichten.dePHAXIAM Provides Business and Financial Update For the First Half of 2024September 25, 2024 | globenewswire.comResults of the Combined General Meeting of 28 June 2024June 28, 2024 | globenewswire.comPHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024June 7, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM provides Business and Financial Update for the First Quarter of 2024May 15, 2024 | finanznachrichten.dePHAXIAM provides Business and Financial Update for the First Quarter of 2024May 15, 2024 | globenewswire.comPhaxiam enrols first patient in endocarditis infection studyApril 15, 2024 | msn.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPrice Targets on NVIDIA Rise in Front of EarningsBy Sarah Horvath | February 24, 2025View Price Targets on NVIDIA Rise in Front of EarningsSuper Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?By Leo Miller | March 6, 2025View Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?Super Micro Computer Shares Surge on Compliance NewsBy Jeffrey Neal Johnson | February 26, 2025View Super Micro Computer Shares Surge on Compliance NewsWalgreens Boots Alliance: Don’t Write Off This Asset Champ YetBy Jea Yu | March 11, 2025View Walgreens Boots Alliance: Don’t Write Off This Asset Champ Yet3 Stocks Using Bitcoin to Grow Their Treasury ReservesBy Jea Yu | February 28, 2025View 3 Stocks Using Bitcoin to Grow Their Treasury ReservesORTX, LIAN, PHXM, and KLDO Company DescriptionsKaleido Biosciences NASDAQ:KLDO$0.0001 0.00 (0.00%) As of 09:31 AM EasternKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.LianBio NASDAQ:LIAN$0.20 0.00 (-2.15%) As of 03/12/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Orchard Therapeutics NASDAQ:ORTXOrchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 03/7/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Market Overreacts, But Guidewire’s Growth Story Remains Strong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
